


**-Amendment to the Claims-**

Amend claims 1, 3, 4, 8 - 11, 13, 15, 17, and 19; cancel claims 18 and 20 - 22; and add new claims 23 - 32 as follows:

1. (Currently amended): A compound of Formula (1.0.0):



— wherein —

-j is 0 or 1; provided that when j is 0, n must be 2;


-k is 0 or 1

-m is 0, 1, or 2;

-n is 1 or 2;

-A has the following meanings:

-(a) a member selected from the group consisting of partial Formulas (1.1.1) through (1.1.5):



(1.1.1)

(1.1.2)

(1.1.3)

(1.1.4)

(1.1.5)

— wherein —

--"\*" indicates the point of attachment of each partial Formula (1.1.1) through (1.1.5) to the remaining portion of Formula (1.0.0);

--q is 1, 2, or 3, provided that where q is 2 or 3, R<sup>q</sup> has the meaning of -H in at least one instance, or two instances, respectively;

--v 0 or 1;

--W<sup>3</sup> is --O--; --N(R<sup>9</sup>)--, where R<sup>9</sup> has the same meaning as defined below; or --OC(=O)--;

--R<sup>7</sup>

is a member independently selected from the group consisting of

— the following: —

—(1) —H;

—(2) —(C<sub>1</sub>-C<sub>6</sub>) alkyl; —(C<sub>2</sub>-C<sub>6</sub>) alkenyl; or —(C<sub>2</sub>-C<sub>6</sub>) alkynyl; where said alkyl, alkenyl or alkynyl is substituted by 0 to 3 substituents R<sup>10</sup>;

— where —

---R<sup>10</sup> is a member selected from the group consisting of phenyl; pyridyl; —F; —Cl; —CF<sub>3</sub>; oxo (=O); —OR<sup>16</sup>; —NO<sub>2</sub>; —CN; —C(=O)OR<sup>16</sup>; —O-C(=O)R<sup>16</sup>; —C(=O)NR<sup>16</sup>R<sup>17</sup>; —O-C(=O)NR<sup>16</sup>R<sup>17</sup>; —NR<sup>16</sup>R<sup>17</sup>; —NR<sup>16</sup>C(=O)R<sup>17</sup>; —NR<sup>16</sup>C(=O)OR<sup>17</sup>; —NR<sup>16</sup>S(=O)<sub>2</sub>R<sup>17</sup>; and —S(=O)<sub>2</sub>NR<sup>16</sup>R<sup>17</sup>; where said phenyl or pyridyl is substituted by 0 to 3 R<sup>12</sup>;

— where —

----R<sup>12</sup> is —F; —Cl; —CF<sub>3</sub>; —CN; —NO<sub>2</sub>; —OH; —(C<sub>1</sub>-C<sub>3</sub>) alkoxy; —(C<sub>1</sub>-C<sub>3</sub>) alkyl; or —NR<sup>16</sup>R<sup>17</sup>;

— and —

----R<sup>16</sup> and R<sup>17</sup> are each a member independently selected from the group consisting of —H; —(C<sub>1</sub>-C<sub>4</sub>) alkyl; —(C<sub>2</sub>-C<sub>4</sub>) alkenyl; —(C<sub>3</sub>-C<sub>6</sub>) cycloalkyl; phenyl; benzyl; and pyridyl; wherein said alkyl, alkenyl, cycloalkyl, phenyl, benzyl, or pyridyl is substituted by 0 to 3 substituents selected from the group consisting of —F, —Cl, —CF<sub>3</sub>, —CN, and —(C<sub>1</sub>-C<sub>3</sub>) alkyl;

—(3) —(CH<sub>2</sub>)<sub>u</sub>—(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl where u is 0, 1 or 2; and further where said (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl is substituted by 0 to 3 substituents R<sup>10</sup> where R<sup>10</sup> has the same meaning as defined above;

— and —

—(4) phenyl or benzyl, where said phenyl or benzyl is independently substituted by 0 to 3 substituents R<sup>10</sup> where R<sup>10</sup> has the same meaning as defined above;

--R<sup>8</sup> is a member independently selected from the group consisting of

— the following: —

---(1) tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; oxazolyl; isoxazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; thiazolyl; isothiazolyl; thiadiazolyl; morpholinyl; parathiazinyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl;

— and —

---(2) indolyl; indolinyl; isoindolinyl; benzo[*b*]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2*H*-1-benzopyranyl; 2-*H*-chromenyl; chromanyl; benzothienyl; 1*H*-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-*d*]pyrimidinyl; pyrimido[4,5-*d*]pyrimidinyl; imidazo[1,2-*a*]pyridinyl; pyridopyridinyl; pteridinyl; and 1*H*-purinyl;

— where —

any moiety recited in (1) or (2) above is optionally substituted with respect to (i) any one or more carbon atoms thereof optionally by a substituent R<sup>14</sup> where R<sup>14</sup> has the same meaning as defined below; (ii) any one or more nitrogen atoms thereof that is not a point of attachment of said moiety, optionally by a substituent R<sup>15</sup> where R<sup>15</sup> has the same meaning as defined below, and all tautomer forms, and optionally N-oxide forms, thereof; and (iii) any sulfur atom thereof that is not a point of attachment of said moiety, by 0, 1, or 2 oxygen atoms;

— and further where —

----R<sup>14</sup> is a member selected from the group consisting of -(C<sub>1</sub>-C<sub>4</sub>) alkyl; -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl; phenyl; benzyl; pyridyl; and quinolinyl; where said alkyl, cycloalkyl, phenyl, benzyl, pyridyl, or quinolinyl is substituted by 0, 1, or 2 substituents -F, -Cl, -CH<sub>3</sub>, -OR<sup>16</sup>, -NO<sub>2</sub>, -CN, or -NR<sup>16</sup>R<sup>17</sup>; and said R<sup>14</sup> group further consists of -F; -Cl; -CF<sub>3</sub>; oxo (=O); -OR<sup>16</sup>; -NO<sub>2</sub>; -CN; -C(=O)OR<sup>16</sup>; -O-C(=O)R<sup>16</sup>; -C(=O)NR<sup>16</sup>R<sup>17</sup>; -O-C(=O)NR<sup>16</sup>R<sup>17</sup>; -NR<sup>16</sup>R<sup>17</sup>; -NR<sup>16</sup>C(=O)R<sup>17</sup>; -NR<sup>16</sup>C(=O)OR<sup>17</sup>; -NR<sup>16</sup>S(=O)<sub>2</sub>R<sup>17</sup>; and -S(=O)<sub>2</sub>NR<sup>16</sup>R<sup>17</sup>;

— and still further where —

----R<sup>15</sup> is a member independently selected from the group consisting of -H; -NR<sup>16</sup>R<sup>17</sup>; -C(=O)R<sup>16</sup>; -OR<sup>16</sup>; -(C<sub>1</sub>-C<sub>4</sub>) alkyl-OR<sup>16</sup>; -C(=O)OR<sup>16</sup>; -(C<sub>1</sub>-C<sub>2</sub>) alkyl-C(=O)OR<sup>16</sup>; -C(=O)NR<sup>16</sup>R<sup>17</sup>; -(C<sub>1</sub>-C<sub>4</sub>) alkyl; -(C<sub>2</sub>-C<sub>4</sub>) alkenyl; -(CH<sub>2</sub>)<sub>u</sub>-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl where u is 0, 1 or 2; phenyl; benzyl; pyridyl; and quinolinyl; wherein said alkyl, alkenyl, alkoxy, cycloalkyl, phenyl, benzyl, pyridyl or quinolinyl is substituted with 0 to 3 substituents R<sup>11</sup>; where R<sup>16</sup> and R<sup>17</sup> have the same meanings as defined above; and

— where —

----R<sup>11</sup> is a member independently selected from the group consisting of -F; -Cl; -CO<sub>2</sub>R<sup>18</sup>; -OR<sup>16</sup>; -CN; -C(=O)NR<sup>18</sup>R<sup>19</sup>; -NR<sup>18</sup>R<sup>19</sup>; -NR<sup>18</sup>C(=O)R<sup>19</sup>; -NR<sup>18</sup>C(=O)OR<sup>19</sup>; -NR<sup>18</sup>S(=O)<sub>p</sub>R<sup>19</sup>; -S(=O)<sub>p</sub>NR<sup>18</sup>R<sup>19</sup>, where p is 1 or 2; -(C<sub>1</sub>-C<sub>4</sub>) alkyl; and -(C<sub>1</sub>-C<sub>4</sub>) alkoxy, where R<sup>11</sup> has the meaning of -OR<sup>16</sup> above and R<sup>16</sup> is defined as -(C<sub>1</sub>-C<sub>4</sub>) alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents independently selected from -F; -Cl; -(C<sub>1</sub>-C<sub>2</sub>) alkoxy carbonyl; -(C<sub>1</sub>-C<sub>2</sub>) alkyl carbonyl; and -(C<sub>1</sub>-C<sub>2</sub>) alkyl carbonyloxy;

— where —

-----R<sup>18</sup> and R<sup>19</sup> are independently selected from the group consisting of -H; -(C<sub>1</sub>-C<sub>4</sub>) alkyl; and phenyl;

--R<sup>9</sup> is a member selected from the group consisting of -H; -(C<sub>1</sub>-C<sub>4</sub>) alkyl; -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl; phenyl; benzyl; pyridyl; -C(=O)OR<sup>18</sup>; -C(=O)R<sup>18</sup>; -OR<sup>18</sup>; -(C<sub>1</sub>-C<sub>2</sub>) alkyl-OR<sup>18</sup>; and -(C<sub>1</sub>-C<sub>2</sub>) alkyl-C(=O)OR<sup>18</sup>; where R<sup>18</sup> has the same meaning as defined above;

— or A has the meaning —

-(b) a moiety comprising a member selected from the group consisting of -O-P(=O)(OH)<sub>2</sub> (phosphoric); -PH(=O)OH (phosphinic); -P(=O)(OH)<sub>2</sub> (phosphonic); -[P(=O)(OH)-O(C<sub>1</sub>-C<sub>4</sub>) alkyl] (alkylphosphono); -P(=O)(OH)-O(C<sub>1</sub>-C<sub>4</sub>) alkyl (alkylphosphinyl); -P(=O)(OH)NH<sub>2</sub> (phosphoramido); -P(=O)(OH)NH(C<sub>1</sub>-C<sub>4</sub>) alkyl and -P(=O)(OH)NHR<sup>25</sup> (substituted phosphoramido); -O-S(=O)<sub>2</sub>OH (sulfuric); -S(=O)<sub>2</sub>OH (sulfonic); -S(=O)<sub>2</sub>NHR<sup>25</sup> (arylsulfonamido); -S(=O)<sub>2</sub>NHR<sup>26</sup>; and acylsulfonamido selected from the group consisting of -C(=O)NHS(=O)<sub>2</sub>R<sup>26</sup>; -C(=O)NHS(=O)<sub>2</sub>NH<sub>2</sub>; -C(=O)NHS(=O)<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub>) alkyl; -C(=O)NHS(=O)<sub>2</sub>NH(C<sub>1</sub>-C<sub>4</sub>) alkyl; -C(=O)NHS(=O)<sub>2</sub>N[(C<sub>1</sub>-C<sub>4</sub>) alkyl]<sub>2</sub>; -S(=O)<sub>2</sub>NHC(=O)(C<sub>1</sub>-C<sub>4</sub>) alkyl; -S(=O)<sub>2</sub>NHC(=O)NH<sub>2</sub>; -S(=O)<sub>2</sub>NHC(=O)NH(C<sub>1</sub>-C<sub>4</sub>) alkyl; -S(=O)<sub>2</sub>NHC(=O)N[(C<sub>1</sub>-C<sub>4</sub>) alkyl]<sub>2</sub>; -S(=O)<sub>2</sub>NHC(=O)R<sup>25</sup>; -S(=O)<sub>2</sub>NHCN; -S(=O)<sub>2</sub>NHC(=S)NH<sub>2</sub>; -S(=O)<sub>2</sub>NHC(=S)NH(C<sub>1</sub>-C<sub>4</sub>) alkyl; -S(=O)<sub>2</sub>NHC(=S)N[(C<sub>1</sub>-C<sub>4</sub>) alkyl]<sub>2</sub>; and -S(=O)<sub>2</sub>NHS(=O)<sub>2</sub>R<sup>25</sup>;

— where —

---R<sup>25</sup> is -H; -(C<sub>1</sub>-C<sub>4</sub>) alkyl; phenyl; or -OR<sup>18</sup>;

-W is —O—; —S(=O)<sub>t</sub>—, where t is 0, 1, or 2; or -N(R<sup>3</sup>)— where R<sup>3</sup> has the same meaning as defined below;

-Y is —C(R<sup>1a</sup>)—, where R<sup>1a</sup> has the same meaning as defined below; or —[N<sup>+(O)<sub>k</sub></sup>— where k is 0 or 1;

— where —

--R<sup>1a</sup> is a member selected from the group consisting of -H; -F; -Cl; -CN; -NO<sub>2</sub>; -(C<sub>1</sub>-C<sub>4</sub>) alkyl; -(C<sub>2</sub>-C<sub>4</sub>) alkynyl; fluorinated-(C<sub>1</sub>-C<sub>3</sub>) alkyl; fluorinated-(C<sub>1</sub>-C<sub>3</sub>) alkoxy; -OR<sup>16</sup>; and -C(=O)NR<sup>12a</sup>R<sup>12b</sup>;

— where —


---R<sup>12a</sup> and R<sup>12b</sup> are each independently -H; -CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; -CH<sub>2</sub>(CH<sub>3</sub>)<sub>2</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>; -C(CH<sub>3</sub>)<sub>3</sub>; cyclopropyl; cyclobutyl; or cyclopentyl;

-R<sup>A</sup> and R<sup>B</sup> are each a member independently selected from the group consisting of -H; -F; -CF<sub>3</sub>; -(C<sub>1</sub>-C<sub>4</sub>) alkyl; -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl,

phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents  $R^{10}$  where  $R^{10}$  has the same meaning as defined above;

— or —

$-R^A$  and  $R^B$  are taken together, but only in the case where  $m$  is 1, to form a spiro moiety of Formula (1.2.0):



(1.2.0)

— where —

$-r$  and  $s$  are independently 0 to 4 provided that the sum of  $r + s$  is at least 1 but not greater than 5;

— and —

$-X^A$  is  $-CH_2-$ ,  $-CHR^{12}-$ , or  $-C(R^{12})_2-$  where each  $R^{12}$  is selected independently of the other and each has the same meaning as defined above;  $-NR^{15}-$ , where  $R^{15}$  has the same meaning as defined above;  $-O-$ ; or  $-S(=O)_t$ , where  $t$  is 0, 1, or 2; and said spiro moiety is substituted as to any one or more carbon atoms thereof by 0 to 3 substituents  $R^{14}$ , as to a nitrogen atom thereof by 0 or 1 substituent  $R^{15}$ , and as to a sulfur atom thereof by 0 or 2 oxygen atoms;

$-R^C$  and  $R^D$  have the same meaning as defined above for  $R^A$  and  $R^B$  except that one of them must be  $-H$ , and they are selected independently of each other and of  $R^A$  and  $R^B$ ;

$-R^1$  and  $R^2$  may individually or together appear on any ring or rings comprising a meaning of the moiety  $B^2$  as defined below, and  $R^1$  and  $R^2$  are each a member independently selected from the group consisting of  $-H$ ;  $-F$ ;  $-Cl$ ;  $-CN$ ;  $-NO_2$ ;  $-(C_1-C_4)$  alkyl;  $-(C_2-C_4)$  alkynyl; fluorinated  $-(C_1-C_3)$  alkyl;  $-OR^{16}$ ; and  $-C(=O)NR^{12a}R^{12b}$ ; where  $R^{12a}$  and  $R^{12b}$  have the same meanings as defined above;

$-R^3$  is  $-H$ ;  $-(C_1-C_3)$  alkyl; phenyl; benzyl; or  $-OR^{16}$ , where  $R^{16}$  has the same meaning as defined above;

$-R^4$ ,  $R^5$  and  $R^6$  may individually or together appear on any ring or rings comprising a meaning of the moiety  $B^1$  as defined below, and  $R^4$ ,  $R^5$  and  $R^6$  are each a member independently selected from the group consisting of

— the following: —

-(a) —H; provided that R<sup>5</sup> and R<sup>6</sup> are not both —H at the same time; —F; —Cl; -(C<sub>2</sub>-C<sub>4</sub>) alkynyl; -R<sup>16</sup>; -OR<sup>16</sup>; -S(=O)<sub>p</sub>R<sup>16</sup>; -C(=O)R<sup>16</sup>; -C(=O)OR<sup>16</sup>; -OC(=O)R<sup>16</sup>; -CN; -NO<sub>2</sub>; -C(=O)NR<sup>16</sup>R<sup>17</sup>; -OC(=O)NR<sup>16</sup>R<sup>17</sup>; -NR<sup>12</sup><sub>a</sub>C(=O)NR<sup>16</sup>R<sup>17</sup>; -NR<sup>12</sup><sub>a</sub>C(=NR<sup>12</sup>)NR<sup>16</sup>R<sup>17</sup>; -NR<sup>12</sup><sub>a</sub>C(=NCN)NR<sup>16</sup>R<sup>17</sup>; -NR<sup>12</sup><sub>a</sub>C(=N-NO<sub>2</sub>)NR<sup>16</sup>R<sup>17</sup>; -C(=NR<sup>12</sup><sub>a</sub>)NR<sup>16</sup>R<sup>17</sup>; -CH<sub>2</sub>C(=NR<sup>12</sup><sub>a</sub>)NR<sup>16</sup>R<sup>17</sup>; -OC(=NR<sup>12</sup><sub>a</sub>)NR<sup>16</sup>R<sup>17</sup>; -OC(=N-NO<sub>2</sub>)NR<sup>16</sup>R<sup>17</sup>; -NR<sup>16</sup>R<sup>17</sup>; -CH<sub>2</sub>NR<sup>16</sup>R<sup>17</sup>; -NR<sup>12</sup><sub>a</sub>C(=O)R<sup>16</sup>; -NR<sup>12</sup><sub>a</sub>C(=O)OR<sup>16</sup>; =NOR<sup>16</sup>; -NR<sup>12</sup><sub>a</sub>S(=O)<sub>p</sub>R<sup>17</sup>; -S(=O)<sub>p</sub>NR<sup>16</sup>R<sup>17</sup>; and -CH<sub>2</sub>C(=NR<sup>12</sup><sub>a</sub>)NR<sup>16</sup>R<sup>17</sup>;

— where —

--p is 0, 1, or 2; and R<sup>12</sup><sub>a</sub>, R<sup>16</sup>, and R<sup>17</sup> have the same meanings as defined above;


-(b) -(C<sub>1</sub>-C<sub>4</sub>) alkyl; and -(C<sub>1</sub>-C<sub>4</sub>) alkoxy, where R<sup>4</sup>, R<sup>5</sup>, or R<sup>6</sup> has the meaning of -OR<sup>16</sup> under (A) above and R<sup>16</sup> is defined as -(C<sub>1</sub>-C<sub>4</sub>) alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents —F or —Cl; or 0 or 1 substituent (C<sub>1</sub>-C<sub>2</sub>) alkoxy carbonyl—; (C<sub>1</sub>-C<sub>2</sub>) alkyl carbonyl—; or (C<sub>1</sub>-C<sub>2</sub>) alkyl carbonyloxy—;

— and —


-(c) an aryl or heterocyclyl moiety selected from the group consisting of phenyl; benzyl; furanyl; tetrahydrofuran; oxetanyl; thienyl; tetrahydrothienyl; pyrrolyl; pyrrolidinyl; oxazolyl; oxazolidinyl; isoxazolyl; isoxazolidinyl; thiazolyl; thiazolidinyl; isothiazolyl; isothiazolidinyl; pyrazolyl; pyrazolidinyl; oxadiazolyl; thiadiazolyl; imidazolyl; imidazolidinyl; pyridinyl; pyrazinyl; pyrimidinyl; pyridazinyl; piperidinyl; piperazinyl; triazolyl; triazinyl; tetrazolyl; pyranyl; azetidinyl; morpholinyl; parathiazinyl; indolyl; indolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuran; 2-H-chromenyl; chromanyl; benzothienyl; 1-H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzthiazolyl; quinolinyl; isoquinolinyl; phthalazinyl; quinazolinyl; quinoxalinyl; and purinyl; wherein said aryl and heterocyclyl moieties are each independently substituted with 0 to 2 substituents R<sup>14</sup> where R<sup>14</sup> has the same meaning as defined above;

— or in the case where B' is phenyl —


-(d) R<sup>5</sup> and R<sup>6</sup> are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1) through (1.3.15):




(1.3.1)




(1.3.2)




(1.3.3)




(1.3.4)




(1.3.5)




(1.3.6)




(1.3.7)




(1.3.8)




(1.3.9)




(1.3.10)




(1.3.11)




(1.3.12)



(1.3.13)



(1.3.14)



(1.3.15)

— wherein —

—R<sup>20</sup> and R<sup>21</sup> are each a member independently selected from the group consisting of —H; —F; —Cl; —CH<sub>3</sub>; —CH<sub>2</sub>F; —CHF<sub>2</sub>; —CF<sub>3</sub>; —OCH<sub>3</sub>; and —OCF<sub>3</sub>;

—R<sup>23</sup> and R<sup>24</sup> are each independently —H; —CH<sub>3</sub>; —OCH<sub>3</sub>; —CH<sub>2</sub>CH<sub>3</sub>; —OCH<sub>2</sub>CH<sub>3</sub>; —CH<sub>2</sub>(CH<sub>3</sub>); —CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; —CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>; —CH<sub>2</sub>CH(CH<sub>3</sub>); —C(CH<sub>3</sub>); or absent, in which case the dashed line —— represents a double bond, provided that in partial Formula (1.3.11) R<sup>23</sup> and R<sup>24</sup> may not both be absent at the same time;

-B<sup>1</sup> is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic; ~~wherein optionally one carbon atom thereof may be replaced by a heteroatom selected from N, O, and S; and where N is selected, optionally a second carbon atom thereof may be replaced by a heteroatom selected from N, O, or S;~~

— wherein —

said moiety defining B<sup>1</sup> is substituted on any ring or rings thereof by R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, which have the same meaning as defined above;

-B<sup>2</sup> is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic; ~~wherein optionally one carbon atom thereof may be replaced by a heteroatom selected from N, O, and S; and where N is selected, optionally a second carbon atom thereof may be replaced by a heteroatom selected from N, O, or S;~~

— wherein —


said moiety defining B<sup>2</sup> is substituted on any ring or rings thereof by R<sup>1</sup> and R<sup>2</sup>, which have the same meaning as defined above;


provided that when m is 0 and W is O, A is not COOH;

— or —

a pharmaceutically acceptable salt thereof.


2. (Original): A compound according to Claim 1 wherein  $\mathbb{A}$  is a moiety of partial Formula (1.1.4) where  $v$  is 0 or 1, and  $R^8$  is a member selected from the group consisting of partial Formulas (1.1.11) through (1.1.38):






Pyridyl

(1.1.35)




Pyrimidinyl

(1.1.36)



Pyrazinyl

(1.1.37)




pyridazinyl

(1.1.38)


wherein “\*\*” indicates the point of attachment of each partial Formula (1.1.11) through (1.1.38) to the remaining portion of Formula (1.0.0); and wherein each carbon atom of partial Formulas (1.1.11) through (1.1.38) is optionally substituted by a substituent  $R^{14}$ ; and wherein  $R^{14}$  and  $R^{15}$  have the same meaning as defined in Claim 1; and all tautomer forms, and optionally N-oxide forms, thereof.

3. (Currently amended): A compound according to Claim 2 wherein  $R^8$  is a member selected from the group consisting of the following partial Formulas:




Tetrazol-5-yl

(1.1.11)




1,2,4-triazol-3-yl

(1.1.12)




1,2,4-triazol-3-on-5-yl

(1.1.13)




1,2,3-triazol-5-yl

(1.1.14)




Imidazol-2-yl

(1.1.15)




Imidazol-4-yl

(1.1.16)




Imidazolidin-2-on-4-yl

(1.1.17)




1,3,4-oxadiazol-2-on-5-yl


(1.1.19)




4. (Currently amended): A compound according to Claim 3 wherein R<sup>8</sup> is a member selected from the group consisting of the following partial Formulas:




5. (Original): A compound according to Claim 2 wherein R<sup>8</sup> is a member selected from the group consisting of partial Formulas (4.8.1) through (4.8.80):







(4.8.29)




(4.8.30)




(4.8.31)



(4.8.32)




(4.8.33)




(4.8.34)




(4.8.35)




(4.8.36)




(4.8.37)




(4.8.38)




(4.8.39)




(4.8.40)




(4.8.41)




(4.8.42)




(4.8.43)




(4.8.44)




(4.8.45)




(4.8.46)




(4.8.47)




(4.8.49)




(4.8.50)




(4.8.51)




(4.8.48)




(4.8.53)

























(4.8.54)



(4.8.55)




(4.8.56)



6. (Original): A compound according to Claim 1 wherein the group A is a moiety of partial Formula (1.1.4) and v is 0 or 1, wherein the moiety R<sup>8</sup> is a bicyclic heterocyclic group selected from the group consisting of indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; and 1H-purinyl.

7. (Original): A compound according to Claim 6 wherein said  $R^8$  moiety is a member selected from the group consisting of partial Formulas (5.0.1) through (5.0.28):



Imidazo-[1,2-a]-  
pyridinyl  
(5.0.25)





pyridopyridinyl  
(5.0.26)

Pteridinyl  
(5.0.27)













1*H*-purinyl  
(5.0.28)


where “\*” indicates the point of attachment to the remaining portion of Formula (1.0.0); and where each carbon atom is optionally substituted by a substituent R<sup>14</sup>; and where R<sup>14</sup> and R<sup>15</sup> have the same meaning as defined in Claim 1; and all tautomer forms, and optionally N-oxide forms, thereof.

8. (Currently amended): A compound according to Claim 1 wherein the moiety B' is phenyl and R<sup>5</sup> and R<sup>6</sup> are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1), (1.3.11), (1.3.12), and (1.3.15):




9. (Currently amended): A compound according to Claim 1 wherein B' and the substituents R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are selected in such a way that the left-hand terminus of said compound of Formula (1.0.0) is represented by the following partial Formulas (1.8.1) through (1.8.72):







(1.8.13)




(1.8.14)




(1.8.15)




(1.8.16)




(1.8.17)



(1.8.18)




(1.8.19)




(1.8.20)

(1.8.21)




(1.8.22)


(1.8.23)




(1.8.24)




(1.8.25)




(1.8.26)




(1.8.27)




(1.8.28)




(1.8.29)



(1.8.30)




(1.8.31)




(1.8.32)


(1.8.33)




(1.8.33)




(1.8.34)




(1.8.35)




(1.8.36)



(1.8.37)




(1.8.38)



































(1.8.39)




(1.8.40)



10. (Currently amended): A compound according to Claim 1 wherein  $\mathbf{B}^2$  and the substituents  $\mathbf{R}^1$  and  $\mathbf{R}^2$  are selected in such a way that this portion of the right-hand terminus of said compound of Formula (1.0.0) is represented by the following partial Formulas (3.0.1) through (3.0.47):





11. (Currently amended): A compound according to Claim 1 wherein  $\mathbf{B}^1$  and  $\mathbf{B}^2$  are independently phenyl or pyridyl;  $m$  is 1;  $n$  is 1;  $\mathbf{A}$  is a moiety of partial Formula (1.1.1) where  $R^7$  is -H, or -CH<sub>3</sub> or phenyl independently substituted by 0 or 1  $R^{10}$  where  $R^{10}$  is phenyl or pyridyl substituted by 0-2 of -F, -Cl, -OCH<sub>3</sub>, -CN, -NO<sub>2</sub>, or -NR<sup>16</sup>R<sup>17</sup> where R<sup>16</sup> and R<sup>17</sup> are -H or -CH<sub>3</sub>; or  $R^{10}$  is -F, -Cl, -CF<sub>3</sub>, -CN, -OCH<sub>3</sub>, -NO<sub>2</sub>, or -C(=O)OR<sup>16</sup>, -NR<sup>16</sup>R<sup>17</sup>, or -S(=O)<sub>2</sub>NR<sup>16</sup>R<sup>17</sup> where R<sup>16</sup> and R<sup>17</sup> are -H or -CH<sub>3</sub>;  $R^9$  is -H or -CH<sub>3</sub>;  $W$  is -O-;  $Y$  is  $=C(R^4_a)$ ; R<sup>1</sup><sub>a</sub> is -H, or -F; R<sup>A</sup> and R<sup>B</sup> are independently -H or -CH<sub>3</sub>; or R<sup>A</sup> and R<sup>B</sup> are taken together to form a -(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl-spiro moiety; one of R<sup>C</sup> and R<sup>D</sup> is -H and the other is -H or -CH<sub>3</sub>; R<sup>1</sup> and R<sup>2</sup> are -H, -F, or -OCH<sub>3</sub>; R<sup>3</sup> is -H or -CH<sub>3</sub>; and R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are -H provided that R<sup>5</sup> and R<sup>6</sup> are not both -H at the same time, -F, -Cl, -OCH<sub>3</sub>, -CN, -NO<sub>2</sub>, or -C(=O)R<sup>3</sup> or -C(=O)OR<sup>3</sup> where R<sup>3</sup> is -CH<sub>3</sub>; or R<sup>5</sup> and R<sup>6</sup> are taken together to form a moiety of partial Formula (1.3.1), (1.3.2), 1.3.3), (1.3.11), (1.3.12), or (1.3.15).

12. (Original): A compound according to Claim 11 wherein R<sup>7</sup> is -H; R<sup>9</sup> is -H; R<sup>A</sup> and R<sup>B</sup> are both -CH<sub>3</sub>, or taken together are a cyclopropyl-spiro moiety; R<sup>C</sup> and R<sup>D</sup> are both -H; R<sup>3</sup> is -H; R<sup>4</sup> is -H; R<sup>5</sup> is -H, -F, -Cl, -CN, -OCH<sub>3</sub>, -C(=O)CH<sub>3</sub>, or -NO<sub>2</sub>; R<sup>6</sup> is -H, provided that R<sup>5</sup> and R<sup>6</sup> are not both -H at the same time, or -F; or R<sup>5</sup> and R<sup>6</sup> are taken together to form

a moiety of partial Formula (1.3.1), or partial Formula (1.3.11) where  $R^{23}$  and  $R^{24}$  are both absent.

13. (Currently amended): A compound according to Claim 1 wherein  $B^1$  and  $B^2$  are independently phenyl or pyridyl;  $m$  is 1;  $n$  is 1;  $A$  is a moiety of partial Formula (1.1.3) where  $R^7$  is -H, or  $-CH_3$  or phenyl independently substituted by 0 or 1  $R^{10}$  where  $R^{10}$  is pyridyl or phenyl substituted by 0-2 of -F, -Cl,  $-OCH_3$ , -CN,  $-NO_2$ , or  $-NR^{16}R^{17}$  where  $R^{16}$  and  $R^{17}$  are -H or  $-CH_3$ ; or  $R^{10}$  is -F, -Cl,  $-CF_3$ , -CN,  $-OCH_3$ ,  $-NO_2$ ,  $-C(=O)OR^{16}$ ,  $-NR^{16}R^{17}$ , or  $-S(=O)_2NR^{16}R^{17}$  where  $R^{16}$  and  $R^{17}$  are -H or  $-CH_3$ ;  $R^9$  is -H or  $-CH_3$ ;  $W$  is  $-O-$ ;  $Y$  is  $=C(R^4_a)$ ;  $R^1_a$  is -H; or -F;  $R^A$  and  $R^B$  are independently -H or  $-CH_3$ ; or  $R^A$  and  $R^B$  are taken together to form a  $-(C_3-C_7)$  cycloalkyl-spiro moiety; one of  $R^C$  and  $R^D$  is -H and the other is -H or  $-CH_3$ ;  $R^1$  and  $R^2$  are -H, -F, or  $-OCH_3$ ;  $R^3$  is -H or  $-CH_3$ ; and  $R^4$ ,  $R^5$  and  $R^6$  are -H provided that  $R^5$  and  $R^6$  are not both -H at the same time, -F, -Cl,  $-OCH_3$ , -CN;  $-NO_2$ , or  $-C(=O)R^3$  or  $-C(=O)OR^3$  where  $R^3$  is  $-CH_3$ ; or  $R^5$  and  $R^6$  are taken together to form a moiety of partial Formula (1.3.1), (1.3.2), (1.3.3), (1.3.11), (1.3.12), or (1.3.15), where for partial Formulas (1.3.11), (1.3.12), and (1.3.15),  $R^{23}$  and  $R^{24}$  are both absent.

14. (Original): A compound according to Claim 13 wherein  $R^7$  is -H;  $R^9$  is -H;  $R^A$  and  $R^B$  are taken together to form a cyclopropyl-spiro or cyclobutyl-spiro moiety;  $R^C$  and  $R^D$  are both -H;  $R^3$  is -H;  $R^4$  and  $R^5$  are both -H, and  $R^6$  is -F; or  $R^5$  and  $R^6$  are taken together to form a moiety of partial Formula (1.3.1) or (1.3.11).

15. (Currently amended): A compound according to Claim 1 wherein  $B^1$  and  $B^2$  are independently phenyl or pyridyl;  $m$  is 1;  $n$  is 1;  $A$  is a moiety of partial Formula (1.1.4) where  $v$  is 0 or 1, and  $R^8$  is tetrazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-3-on-5-yl, 1,2,3-triazol-5-yl, imidazol-2-yl, imidazol-4-yl, imidazolidin-2-on-4-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-on-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-on-5-yl, 1,3,4-oxadiazolyl, 1,3,4-oxadiazol-2-on-5-yl, oxazolyl, isoxazolyl, pyrrolyl, pyrazolyl, succinimidyl, glutarimidyl, pyrrolidonyl, 2-piperidonyl, 2-pyridonyl, 4-pyridonyl, pyridazin-3-onyl, thiadiazolyl, parathiazinyl, pyridyl, pyrimidinyl, pyrazinyl, or pyridazinyl, all of which are independently substituted by 0 or 1  $R^{14}$  where  $R^{14}$  is  $-(C_1-C_3)$  alkyl, phenyl, or pyridyl, each of which is independently substituted by 0-2 of -F, -Cl,  $-OCH_3$ , -CN,  $-NO_2$ , or  $-NR^{16}R^{17}$  where  $R^{16}$  and  $R^{17}$  are -H or  $-CH_3$ ; or  $R^{14}$  is -F, -Cl,  $-CF_3$ , -CN,  $-OCH_3$ ,  $-NO_2$ , or  $-C(=O)OR^{16}$ ,  $-NR^{16}R^{17}$ , or  $-S(=O)_2NR^{16}R^{17}$  where  $R^{16}$  and  $R^{17}$  are -H or  $-CH_3$ ;  $R^9$  is -H or  $-CH_3$ ;  $W$  is  $-O-$ ;  $Y$  is  $=C(R^4_a)$ ;  $R^1_a$  is -H; or -F;  $R^A$  and  $R^B$  are independently -H or  $-CH_3$ ; or  $R^A$  and  $R^B$  are taken together to form a  $-(C_3-C_7)$  cycloalkyl-spiro moiety; one of  $R^C$  and  $R^D$  is -H and the other is -H or  $-CH_3$ ;  $R^1$  and  $R^2$  are -H, -F, or  $-OCH_3$ ;  $R^3$  is -H or  $-CH_3$ ; and  $R^4$ ,  $R^5$  and  $R^6$  are -H provided that  $R^5$  and  $R^6$  are not both -H at the same time, -F, -Cl,  $-OCH_3$ , -CN;

-NO<sub>2</sub>, or -C(=O)R<sup>3</sup> or -C(=O)OR<sup>3</sup> where R<sup>3</sup> is -CH<sub>3</sub>; or R<sup>5</sup> and R<sup>6</sup> are taken together to form a moiety of partial Formula (1.3.1), (1.3.2), (1.3.3), (1.3.11), (1.3.12), or (1.3.15).

16. (Original): A compound according to Claim 15 wherein v is 0, R<sup>8</sup> is tetrazol-5-yl, 1,2,3-triazol-5-yl, or pyridyl; R<sup>C</sup> and R<sup>D</sup> are both -H; R<sup>3</sup> is -H; R<sup>4</sup> and R<sup>5</sup> are both -H, and R<sup>6</sup> is -F; or R<sup>5</sup> and R<sup>6</sup> are taken together to form a moiety of partial Formula (1.3.1) or (1.3.11).

17. (Currently amended): A compound of according to Claim 1 wherein said compound is ~~a member selected from the group consisting of the following:~~

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-acetic acid methyl ester ~~of Formula (6.0.30)~~;

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-2-methyl-propionic acid methyl ester ~~of Formula (6.0.31)~~;

2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-2-methyl-propionic acid methyl ester ~~of Formula (6.0.32)~~;

[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-acetic acid methyl ester ~~of Formula (6.0.35)~~;

1-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-cyclobutanecarboxylic acid ethyl ester ~~of Formula (6.0.36)~~;

1-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-cyclopropanecarboxylic acid ethyl ester ~~of Formula (6.0.37)~~;

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-acetic acid methyl ester ~~of Formula (6.0.38)~~;

1-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-cyclopropanecarboxylic acid ethyl ester ~~of Formula (6.0.39)~~;

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-2-methyl-propionic acid ~~of Formula (6.5.1)~~;

2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-2-methyl-propionic acid ~~of Formula (6.5.2)~~;

1-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-cyclobutanecarboxylic acid ~~of Formula (6.5.3)~~;

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-2-methyl-propionic acid ~~of Formula (6.5.4)~~;

2-[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-2-methyl-propionic acid *ef Formula (6.5.5)*;

1-[4-({[2-(Benzodioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-cyclopropanecarboxylic acid *ef Formula (6.5.6)*;

2-[4-({[2-(Benzodioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-propionic acid *ef Formula (6.5.7)*;

2-[4-({[2-(Benzodioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-methoxy-phenyl]-2-methyl-propionic acid *ef Formula (6.5.8)*;

2-[4-({[2-(Benzodioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-methoxy-phenyl]-2-methyl-propionic acid *ef Formula (6.5.9)*;

2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-3-methoxy-phenyl]-2-methyl-propionic acid *ef Formula (6.5.10)*;

[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-acetic acid *ef Formula (6.5.11)*;

[4-({[2-(Benzodioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-acetic acid *ef Formula (6.5.12)*;

1-[4-({[2-(Benzodioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-cyclopropanecarboxylic acid *ef Formula (6.5.13)*;

[4-({[2-(Benzodioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-acetic acid *ef Formula (6.5.14)*;

[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-acetic acid *ef Formula (6.5.15)*;

[4-({[2-(Benzodioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenyl]-acetic acid *ef Formula (6.5.16)*;

2-[4-({[2-(Benzodioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenyl]-2-methyl-propionic acid *ef Formula (6.5.17)*;

2-(Benzodioxol-5-yloxy)-N-[4-(1-carbamoyl-1-methyl-ethyl)-benzyl]-nicotinamide *ef Formula (6.5.18)*;

2-(Benzodioxol-5-yloxy)-N-(4-carbamoylmethyl-benzyl)-nicotinamide *ef Formula (6.5.19)*;

N-(4-Carbamoylmethyl-2-fluoro-benzyl)-2-(4-fluoro-phenoxy)-nicotinamide *ef Formula (6.5.20)*;

2-(Benzodioxol-5-yloxy)-N-[4-(1-carbamoyl-1-methyl-ethyl)-2-fluoro-benzyl]-nicotinamide *ef Formula (6.5.21)*;

~~N-[4-(1-Carbamoyl-1-methyl-ethyl)-2-fluoro-benzyl]-2-(4-fluoro-phenoxy)-nicotinamide—of Formula (6.5.22);~~

~~2-(4-Fluoro-phenoxy)-N-[2-fluoro-4-(1H-tetrazol-5-ylmethyl)-benzyl]-nicotinamide—of Formula (6.5.23);~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-methyl-1-methylcarbamoyl-ethyl)-benzyl]-nicotinamide of Formula (6.5.24);~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-[1-(cyclopropylmethyl-carbamoyl)-1-methyl-ethyl]-benzyl]-nicotinamide of Formula (6.5.25);~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-ethylcarbamoyl-1-methyl-ethyl)-benzyl]-nicotinamide of Formula (6.5.26);~~

~~2-(4-Fluoro-phenoxy)-N-[4-(1H-tetrazol-5-yl)-benzyl]-nicotinamide of Formula (6.5.27);~~

~~2-(4-Fluoro-phenoxy)-N-[4-[1-methyl-1-(1H-tetrazol-5-yl)-ethyl]-benzyl]-nicotinamide—of Formula (6.5.28);~~

~~N-[2-Fluoro-4-[1-methyl-1-(1H-tetrazol-5-yl)-ethyl]-benzyl]-2-(4-fluoro-phenoxy)-nicotinamide of Formula (6.5.29);~~

~~5-Chloro-2-(4-fluoro-phenoxy)-N-[4-[1-methyl-1-(1H-tetrazol-5-yl)-ethyl]-benzyl]-nicotinamide of Formula (6.5.30);~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-5-chloro-N-[4-[1-methyl-1-(1H-tetrazol-5-yl)-ethyl]-benzyl]-nicotinamide of Formula (6.5.31); and ; or~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-[1-methyl-1-(1H-tetrazol-5-yl)-ethyl]-benzyl]-nicotinamide of Formula (6.5.32).~~

18. (Canceled)

19. (Currently amended): A pharmaceutical composition ~~for use in treating a subject suffering from a disease, disorder or condition mediated by the PDE4 isozyme whereby it regulates the activation and degranulation of eosinophils~~, comprising a therapeutically effective amount of a compound of Formula (1.0.0) as defined in Claim 1 together with a pharmaceutically acceptable carrier therefor.

20. - 22. (Canceled)

Add new claims 23 - 32:

23. (New): A method of treating a disease, disorder or condition mediated by the PDE4 isozyme in a mammal, said method comprising administering to said mammal in need of such mediation, a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.
24. (New): A method of claim 23 wherein said PDE4 isozyme is the PDE4-D subtype isozyme.
25. (New): A method of claim 23 wherein said disease, disorder or condition is atopic asthma; non-atopic asthma; allergic asthma; bronchial asthma; essential asthma; true asthma; intrinsic asthma caused by pathophysiologic disturbances; extrinsic asthma caused by environmental factors; essential asthma of unknown or inapparent cause; bronchitic asthma; emphysematous asthma; exercise-induced asthma; occupational asthma; infective asthma caused by bacterial, fungal, protozoal or viral infection; non-allergic asthma; incipient asthma; or wheezy infant syndrome.
26. (New): A method of claim 23 wherein said disease, disorder or condition is chronic or acute bronchoconstriction; chronic bronchitis; small airways obstruction; emphysema; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary disease; adult respiratory distress syndrome; or exacerbation of airways hyper-reactivity consequent to other drug therapy.
27. (New): A method of claim 26 wherein said chronic obstructive pulmonary disease is characterized by irreversible, progressive airways obstruction.
28. (New): A method of claim 26 wherein said pneumoconiosis is aluminosis; bauxite workers' disease; anthracosis; miners' disease; asbestosis; steam-fitters' asthma; chalcosis; flint disease; ptilosis caused by inhaling the dust from ostrich feathers; siderosis caused by the inhalation of iron particles; silicosis; grinders' disease; byssinosis; cotton-dust asthma; or talc pneumoconiosis.
29. (New): A method of claim 23 wherein said disease, disorder or condition is bronchitis; acute bronchitis; chronic bronchitis; acute laryngotracheal bronchitis; arachidic bronchitis; catarrhal bronchitis; croupus bronchitis; dry bronchitis; infectious asthmatic bronchitis; productive bronchitis; staphylococcus bronchitis; streptococcal bronchitis; or vesicular bronchitis.
30. (New): A method of claim 23 wherein said disease, disorder or condition is bronchiectasis; cylindric bronchiectasis; sacculated bronchiectasis; fusiform bronchiectasis; capillary bronchiectasis; cystic bronchiectasis; dry bronchiectasis or follicular bronchiectasis.
31. (New): A method of claim 23 wherein said disease, disorder or condition is seasonal allergic rhinitis; perennial allergic rhinitis; sinusitis; purulent sinusitis; nonpurulent sinusitis; acute sinusitis; chronic sinusitis; ethmoid sinusitis; frontal sinusitis; or sphenoid sinusitis.
32. (New): A method of claim 23 wherein said disease, disorder or condition is regulated by the activation and degranulation of eosinophils.